Share on StockTwits

Johnson & Johnson (NYSE:JNJ)‘s stock had its “equal weight” rating reaffirmed by analysts at Barclays in a research report issued to clients and investors on Wednesday. They currently have a $102.00 price objective on the stock, up from their previous price objective of $99.00. Barclays’ price objective indicates a potential downside of 3.65% from the company’s current price.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.01% on Wednesday, hitting $105.86. 3,729,605 shares of the company’s stock traded hands. Johnson & Johnson has a 1-year low of $85.50 and a 1-year high of $106.00. The stock’s 50-day moving average is $102.6 and its 200-day moving average is $96.62. The company has a market cap of $299.5 billion and a P/E ratio of 20.25.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $1.54 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.48 by $0.06. The company had revenue of $18.10 billion for the quarter, compared to the consensus estimate of $18.00 billion. During the same quarter last year, the company posted $1.44 earnings per share. Johnson & Johnson’s revenue was up 3.5% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post $5.89 EPS for the current fiscal year.

A number of other firms have also recently commented on JNJ. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday. They now have a $108.00 price target on the stock, up previously from $100.00. Separately, analysts at Deutsche Bank raised their price target on shares of Johnson & Johnson from $52.00 to $53.00 in a research note on Tuesday, May 20th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Thursday, May 8th. They now have a $106.00 price target on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $92.47.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.